Evaluating Prognostic Factor Studies in Veterinary Medicine

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Prognostic factor studies aim to identify patient, tumor, or treatment characteristics that independently predict clinical outcomes such as survival or recurrence, distinct from diagnostic markers. Prospective cohort studies are preferred for their ability to control timing and reduce bias, though well-conducted retrospective cohorts with explicit bias mitigation are acceptable.
• Sample size for time-to-event analyses, particularly using Cox regression, is dictated by the number of outcome events, with a minimum of 10 events per predictor variable recommended, and ideally 15-20 for robust estimates and acceptable confidence interval coverage.
• Candidate prognostic factors must have a plausible biological rationale linking them to the outcome, and their measurement should be objective, reproducible, and ideally blinded to outcome status to prevent measurement bias.
• Statistical models must account for established prognostic factors to demonstrate independent predictive value, and internal validation techniques like bootstrapping are crucial to assess and correct for overfitting in multivariable models before external claims are made.
• Transparent reporting, adhering to guidelines like STROBE-Vet for observational studies, is essential for critical appraisal, allowing evaluation of study design, population representativeness, outcome ascertainment, and analytical rigor to determine clinical actionability.
• The clinical utility of a prognostic factor is determined by whether it changes management or risk stratification beyond established predictors, requiring validation in an independent cohort and demonstration of incremental predictive value.

Prognostic factor studies identify patient, tumor, or treatment characteriztics associated with clinical outcomes such as survival, recurrence, or metastasis. These studies underpin clinical decision-making in veterinary oncology, internal medicine, and surgery, yet their methodological quality varies widely. This article provides a structured framework for designing, conducting, and critically appraising prognostic factor research across species. It is written for veterinary researchers who need to evaluate whether a reported prognostic marker is credible, reproducible, and clinically actionable.

The central question addressed is deceptively simple: does a measured factor independently predict outcome after adjustment for established predictors? Answering that question requires attention to study design, sample size, handling of missing data, choice of statistical model, and transparent reporting. A prognostic factor that appears significant in an underpowered or poorly controlled study may fail to replicate, wasting clinical and financial resources. Conversely, a genuinely informative marker can refine prognosis, guide adjuvant therapy decisions, and identify targets for intervention. The framework presented here applies to any species and any outcome, from canine soft tissue sarcoma recurrence to feline chronic kidney disease progression.

At a Glance

The Scientific Basis of Prognostic Factor Research

Prognostic factors differ from diagnostic markers in a fundamental way. A diagnostic marker distinguishes diseased from non-diseased animals at a point in time. A prognostic factor stratifies outcome among animals that already share a diagnosis. The distinction matters because the study designs, statistical methods, and reporting requirements differ accordingly.

The biological rationale for a prognostic factor must be explicit before data collection begins. In veterinary oncology, for example, histologic grade, mitotic index, and surgical margin status have well-established prognostic value for canine soft tissue sarcomas, with high mitotic index predicting reduced survival time and complete margins predicting nonrecurrence. Molecular markers such as steroid receptor expression, proliferation markers, and p53 mutations have been investigated in canine mammary tumors because they mirror prognostic pathways in human breast cancer. A candidate factor should have a plausible mechanism linking it to the outcome, whether that mechanism is tumor biology, host response, or treatment response.

Distinguishing Prognostic From Predictive Factors

A prognostic factor informs outcome regardless of treatment. A predictive factor informs differential treatment response. The distinction has direct therapeutic consequences. A prognostic marker such as tumor stage justifies more intensive monitoring or adjuvant therapy in high-risk animals. A predictive marker such as a specific receptor status identifies which therapy is more likely to work. Many published studies conflate the two, and the conflation leads to clinical recommendations that exceed the evidence.

Study Design Considerations

The prospective cohort study is the reference design for prognostic factor research. Animals are enrolled at a defined point in their disease course, predictors are measured at baseline, and outcomes are ascertained during follow-up. This design controls the timing of predictor measurement, reduces recall and measurement bias, and allows standardized outcome assessment. Prospective enrollment is feasible for common conditions with predictable referral patterns, such as canine lymphoma or feline chronic kidney disease.

Retrospective cohort studies using medical records or tissue archives are more common in veterinary medicine because they are faster and less expensive. They are acceptable when the predictor is a stable analyte such as histologic grade or immunohistochemical expression, and when outcome data are reliably recorded. The limitations are substantial. Records may lack standardized staging, follow-up may be incomplete, and animals lost to follow-up may differ systematically from those with complete data. A retrospective study should state explicitly how missing data were handled and should compare the characteriztics of animals with and without complete follow-up.

Selection of the Study Population

The study population must be defined by explicit inclusion and exclusion criteria that reflect the clinical question. If the question concerns all dogs with soft tissue sarcoma, the population should include all histologic grades, all anatomic sites, and all treatment protocols. If the question concerns a specific subgroup, such as grade III tumors treated with surgery alone, the criteria must be narrow enough to avoid confounding by treatment variation. The source population, referral filter, and enrollment period should be described so that readers can judge generalizability.

Sample Size and Statistical Power

Sample size calculation for prognostic factor studies is governed by the number of outcome events, not the total number of animals. For time-to-event analyzes using Cox proportional hazards regression, the conventional minimum is 10 events per predictor variable examined. At 10 events per variable, regression coefficients may be biased in either direction. At 15 to 20 events per variable, bias is acceptably small and confidence intervals have nominal coverage. A study of 200 dogs with 30 deaths can examine at most two predictor variables reliably, regardless of how many variables were measured.

Researchers should report how the sample size was determined, including the assumed effect size, the expected event rate, and the number of candidate predictors. Post hoc power calculations based on observed effects are circular and should be avoided. When a study reports a non-significant association, the confidence interval around the effect estimate reveals whether the result excludes a clinically meaningful effect or merely reflects insufficient power.

Statistical Analysis and Model Building

Cox proportional hazards regression is the standard analytic tool for time-to-event outcomes. The proportional hazards assumption should be tested, and alternative models such as accelerated failure time models considered when the assumption fails. Logistic regression is appropriate for binary outcomes such as recurrence at one year, but it discards time information and is less efficient than survival analysis.

Model building should follow a pre-specified strategy. Candidate predictors should be selected on biological grounds and previous evidence, not by univariable screening alone. Variables with P values below 0.20 in univariable analysis are commonly entered into multivariable models, but this approach can exclude important confounders and include noise variables. A better strategy is to specify the model before analysis, guided by a causal diagram of the presumed relationships among predictors, confounders, and outcome.

Internal Validation and Overfitting

Multivariable models fitted to small datasets overfit, meaning they perform well on the derivation sample but poorly on new animals. Internal validation techniques such as bootstrap resampling or cross-validation estimate the optimizm of the model and provide shrinkage-corrected performance measures. A prognostic model that has not undergone internal validation should be regarded as preliminary. External validation in an independent population is required before the model can be recommended for clinical use.

Reporting Standards and Critical Appraisal

Transparent reporting allows readers to assess the internal and external validity of a prognostic study. The STROBE statement for observational studies and its veterinary extension, STROBE-Vet, specify the items that should be reported for cohort, case-control, and cross-sectional studies. The ARRIVE guidelines 2.0 provide the corresponding standard for animal experiments, including the reporting of sample size justification, randomisation, and blinding. The EQUATOR Network maintains a comprehensive library of reporting guidelines across study types, and researchers should consult the relevant checklist before submission.

When appraising a published prognostic factor study, the reader should ask five questions. Was the study population clearly defined and representative of the target population? Were predictors measured objectively and without knowledge of outcome? Was follow-up complete and outcome ascertainment standardized? Was the sample size adequate for the number of predictors examined? Did the analysis adjust for established prognostic factors and validate the model internally? A study that fails on several of these criteria may still generate hypotheses, but its findings should not change clinical practice without replication.

Practical Appraisal Workflow

A structured appraisal of a prognostic factor study proceeds through four sequential passes. Each pass answers a distinct question, and failure at any stage should prompt cautious interpretation of the reported associations.

Pass 1: Verify the Study Question and Population

Confirm that the study asks a prognostic question instead of a predictive or treatment-effect question. The outcome must be a clinical endpoint such as survival, recurrence, metastasis, or disease progression, measured from a clearly defined time zero. Time zero is the moment of diagnosis, surgery, or study enrollment, and it must be identical for all participants.

Examine the source population and the sampling frame. A prognostic factor study draws its value from the representativeness of its cohort. Hospital-based cohorts are common in veterinary research, but they carry referral bias. Dogs with soft tissue sarcomas referred to specialty centers may have larger tumors or higher histologic grades than the general population of affected dogs, and this skews both the distribution of the candidate factor and the outcome rates Dennis et al. 2011, prognostic factors for soft tissue sarcomas in dogs. Ask whether the authors describe the referral base, the recruitment period, and the proportion of eligible animals that were enrolled. A study that enrols fewer than 80% of eligible animals should justify the exclusions.

Pass 2: Assess Outcome Measurement and Follow-Up

The outcome must be measured with a validated, repeatable method. For survival endpoints, the distinction between overall survival, disease-specific survival, and disease-free interval changes the interpretation. Cause of death must be determined by necropsy or by explicit clinical criteria, not by owner report alone. For recurrence endpoints, the surveillance protocol matters. A study that examines dogs at three-month intervals will detect recurrences earlier than one that relies on owner observation, and this difference can inflate or obscure prognostic associations.

Follow-up completeness is a common failure. Loss to follow-up in veterinary studies often reflects owner financial constraints, euthanasia decisions, or transfer of care. If more than 20% of animals are lost or censored for reasons other than the outcome of interest, the effect estimates are at risk of attrition bias. The authors should report the median follow-up duration and the number at risk at each interval.

Pass 3: Evaluate the Candidate Factor and Its Measurement

The candidate prognostic factor must be measured at time zero or at a clearly defined time point before the outcome occurs. Measurement should be blinded to outcome status. In retrospective studies, the pathologist scoring histologic slides or the clinician reading imaging studies should not know which animals recurred or died. Blinding is especially important for subjective factors such as histologic grade, mitotic count, or immunohistochemical scoring.

Assess the reproducibility of the measurement. For histologic grading systems, the authors should report inter-observer agreement statistics such as the kappa coefficient. A grading system that cannot be reproduced between pathologists has limited clinical utility even if it predicts outcome in the derivation cohort. The study by Dennis and colleagues identified incomplete surgical margins and high mitotic index as prognostic factors for soft tissue sarcomas, but the authors noted that histologic type, tumor dimension, and invasiveness required further investigation because of inconsistent measurement and reporting across studies Dennis et al. 2011, prognostic factors for soft tissue sarcomas in dogs. This illustrates the gap between a factor that is statistically associated with outcome and one that is ready for clinical use.

Pass 4: Scrutinise the Analysis and the Claim

The final pass examines the statistical methods. The analysis must account for follow-up time, which means Kaplan-Meier curves and Cox proportional hazards regression for time-to-event outcomes. A study that reports only the proportion of animals surviving at one year, without accounting for censoring, has discarded information and may mislead.

The multivariable model must include established prognostic factors as covariates. For canine mammary tumors, tumor size, lymph node status, and clinical stage are recognized determinants of outcome, and a new molecular marker should be tested against these variables Queiroga et al. 2011, canine mammary tumors as a model for human breast cancer. A marker that is significant in univariable analysis but loses significance after adjustment for stage has not demonstrated independent prognostic value. The authors should report the full multivariable model, including the hazard ratios, confidence intervals, and the method of variable selection. Stepwise selection procedures are acceptable but should be described explicitly, and the number of events per variable should exceed ten.

Common Failure Modes in Veterinary Prognostic Studies

Several recurring design flaws account for most of the variability in prognostic factor claims across veterinary specialties.

Insufficient events. Veterinary cohorts are often small, and the number of outcome events is smaller still. A study of 60 dogs with 15 deaths can support at most one or two predictor variables in a multivariable model. Authors who enter five or six variables into such a model are overfitting, and the resulting hazard ratios are unstable.

Survivor treatment bias. When the candidate factor is a treatment-related variable, such as surgical margin status or adjuvant therapy, the comparison must account for why some animals received the treatment and others did not. Animals with advanced disease may be less likely to receive aggressive surgery, and this confounds the association between margin status and outcome.

Composite outcomes. Combining recurrence and death into a single endpoint can obscure distinct biological pathways. A factor that predicts local recurrence may not predict metastasis, and combining the two dilutes the signal.

Data-driven cut points. Dichotomising a continuous variable such as mitotic count at the median of the study sample guarantees a statistically significant split in some datasets. The correct approach is to prespecify the cut point from published criteria or to use restricted cubic splines that do not assume linearity.

Reporting Checklists and Their Application

The EQUATOR Network maintains a library of reporting guidelines for health research, including the STROBE statement for observational studies and the REFLECT statement for livestock studies EQUATOR Network reporting guidelines. Veterinary journals increasingly require adherence to these standards, and reviewers should use them as a structured appraisal tool.

For animal studies that involve experimental manipulation, the ARRIVE guidelines 2.0 specify the minimum information required for transparent reporting, including sample size calculation, randomisation, blinding, and the exclusion of animals from analysis ARRIVE guidelines 2.0 for reporting animal research. While ARRIVE applies primarily to experimental studies, its emphasis on reporting the number of animals at each stage of the study and the reasons for exclusion is directly transferable to the appraisal of prognostic cohorts.

A practical checklist for the veterinary reader includes the following items:

Species and Setting Considerations

The appraisal standards do not change across species, but the practical constraints do. In companion animal oncology, the outcome is often owner-directed euthanasia, which is a subjective endpoint influenced by financial capacity, owner perception of quality of life, and clinician recommendation. A prognostic factor study that uses overall survival in dogs or cats is therefore measuring a composite of biological progression and owner decision-making. Disease-specific survival or progression-free interval may be more biologically informative, but these endpoints require more intensive monitoring.

In livestock and production animal medicine, the unit of analysis may be the herd instead of the individual animal. Prognostic factors for disease outcomes in cattle or poultry often operate at the group level, and the statistical analysis must account for clustering. Ignoring herd-level clustering produces artificially narrow confidence intervals and spurious significance. The REFLECT guideline addresses these reporting requirements for livestock studies EQUATOR Network reporting guidelines.

In exotic and wildlife medicine, sample sizes are frequently too small for multivariable modeling. A prognostic factor study in these species may be limited to descriptive survival estimates, and the reader should not expect the same level of statistical rigour as in canine or feline oncology. The correct response is not to dismiss such studies but to interpret them as hypothesis-generating and to seek corroboration across multiple independent cohorts.

Documenting the Appraisal

When the appraisal is complete, record the findings in a structured format. State the study design, the population, the outcome definition, the candidate factor, the adjusted effect estimate with confidence interval, and the methodological limitations. Note whether the factor changes clinical management. A prognostic factor that is statistically significant but does not alter treatment decisions, monitoring frequency, or owner communication has limited practical value. The appraisal should conclude with an explicit statement of whether the factor is ready for clinical use, requires validation in an independent cohort, or should be disregarded because of methodological flaws.

Recognized Complications and Early Detection

Prognostic factor studies in veterinary medicine fail in predictable patterns. The most consequential failure is confounding by treatment. Animals with an adverse prognostic factor often receive more aggressive therapy, so the factor appears less harmful than it truly is. Detect this early by asking whether management decisions plausibly depended on the factor's value at enrollment. If so, treatment assignment must enter the model as a covariate or the study should restrict enrollment to animals managed under a uniform protocol.

Loss to follow-up is the second major complication. Veterinary patients move, die at home, or are euthanised without necropsy. When outcome ascertainment depends on owner reporting, missingness is rarely random. Compare the baseline characteriztics of animals with complete follow-up against those lost. A difference in tumor grade, breed, or socioeconomic proxy such as insurance status signals informative censoring. The ARRIVE guidelines for reporting animal research require explicit accounting of excluded animals, and the appraisal should verify that the flow of animals through the study is transparent.

Measurement drift is a third failure mode. Histologic grading performed by one pathologist at the start of a multi-year study may differ from grading performed later, particularly if diagnostic criteria were refined in the interval. Archive the original slides and have a blinded second observer re-score a random subset. Report the kappa statistic. The same logic applies to laboratory assays: batch effects in immunoassays or PCR platforms can masquerade as prognostic signals.

Common Errors and Corrective Action

Less experienced readers often mistake statistical association for clinical utility. A hazard ratio with a narrow confidence interval does not tell you whether the factor changes management. The corrective action is to demand a measure of discrimination, such as the c-statistic, and to compare it against a model containing only established factors. A new marker that adds nothing beyond stage and grade has limited clinical value, even if it is independently associated with outcome.

A second error is overinterpreting subgroup analyzes. Veterinary samples are small, and subgroup effects are frequently spurious. Treat any subgroup claim as hypothesis-generating unless the interaction term was pre-specified and the study was powered for it. The EQUATOR Network reporting guidelines provide the relevant checklists for observational designs, and the appraisal should confirm that the authors followed one.

A third error is confusing the direction of causation in cross-sectional biomarker studies. A marker measured at diagnosis may reflect disease duration instead of predict future behavior. The corrective action is to require a prospective cohort design for prognostic claims. Cross-sectional associations can identify candidate markers, but they cannot establish prognostic value.

Limitations of the Current Evidence

The veterinary prognostic literature is dominated by single-institution retrospective studies with modest sample sizes. External validation is rare. A factor that performs well in one referral population may fail in primary care, where case mix and treatment intensity differ. The canine soft tissue sarcoma literature illustrates this: histologic grade and mitotic index are consistently prognostic, but the precise recurrence estimates vary across studies, and the authors of one major review noted that further research is needed to delineate differences in metastatic rate and median survival between grades. See the prognostic factor analysis of canine soft tissue sarcomas for the original discussion.

Expert opinion still differs on the role of molecular markers. Some investigators argue that markers such as proliferation indices or receptor status should be incorporated into routine staging, while others maintain that their added predictive value over conventional histologic grading is unproven. The comparative oncology literature, such as the review of canine mammary tumors as a model for human breast cancer, suggests that molecular markers are promising, but the veterinary evidence base for most of them remains thin. Acknowledge this uncertainty instead of forcing a consensus.

Escalation and Referral

Referral is warranted when the study's validity hinges on specialised expertise that the generalizt cannot provide. A veterinary pathologist should adjudicate histologic grading and margin assessment. A veterinary epidemiologist or biostatistician should review the modeling strategy when the analysis involves competing risks, time-dependent covariates, or complex imputation. Laboratory involvement is required when the candidate factor is a biomarker assay that must be validated for the target species and matrix. The MSD Veterinary Manual professional edition can guide species-specific sample handling and interpretation.

Regulatory reporting applies when the study involves a product subject to pharmacovigilance obligations. If an adverse event is identified during follow-up, the investigator must determine whether reporting to the relevant authority is required. The American Veterinary Medical Association practice resources provide guidance on professional obligations, while the WOAH terrestrial animal health standards govern notifiable disease reporting in international contexts. When in doubt, consult the relevant authority before publication.

Troubleshooting Table

Frequently Asked Questions

How Much Does a Prognostic Factor Study Cost, and Where Should Limited Resources Be Directed?

Costs vary widely with study design, sample size, and assay choice. Prospective cohort studies with biobanked samples and long follow-up are the most expensive. Retrospective studies using archived tissues and medical records reduce cost substantially but introduce selection and measurement biases. If resources are constrained, direct them toward complete outcome ascertainment and blinded factor measurement instead of expanding the candidate factor panel. A smaller study with verified outcomes and minimal loss to follow-up supports stronger inference than a larger study with incomplete records. Consult institutional and grant resources early, as many funding bodies require a data management plan and a prespecified analysis strategy before release of funds.

What Can Be Done When the Ideal Assay or Equipment Is Unavailable?

Use the best available method and document its limitations explicitly. For example, if immunohistochemistry for a specific marker is unavailable, a validated surrogate assay may be acceptable, but the substitution must be justified in the methods and discussed in the limitations. Consider whether the factor can be measured with a different platform, such as ELISA instead of multiplex arrays, or whether a semi-quantitative histologic score can replace a quantitative assay. If the substitute measurement has lower reliability, increase the number of replicate measurements and report the intra- and inter-observer agreement. When the measurement error is substantial, interpret the prognostic estimate with wider confidence intervals and avoid claiming precision the data cannot support.

How Do Prognostic Factor Findings Transfer Across Species or Breeds?

Direct transfer is rarely safe. A factor validated in one species may have different baseline expression, different interactions with other variables, or a different relationship to the outcome in another species. Canine mammary tumors share clinical and molecular features with human breast cancer, including tumor size, lymph node status, and steroid receptor expression, but even this well-studied comparison requires species-specific validation before clinical use. Within a species, breed differences in tumor biology and disease progression can alter the prognostic value of a marker. Treat any cross-species or cross-breed application as a new hypothesis requiring independent confirmation in the target population, not as an established fact.

What Records Should Be Kept During a Prognostic Factor Study?

Maintain a complete audit trail from enrollment through analysis. This includes the original study protocol, amendments with dates and reasons, case report forms, source documents for outcome ascertainment, laboratory reports, and the raw dataset with a data dictionary. Document every exclusion and the reason for it, as exclusions are a common source of selection bias. Record the dates of follow-up contacts and the method used, such as telephone, recheck examination, or medical record review. Keep a log of assay batches, reagent lots, and instrument calibrations. These records support reproducibility, allow independent audit, and are often required by journals and funding bodies. The ARRIVE guidelines specify the minimum information needed for transparent reporting of animal research.

How Should Prognostic Uncertainty Be Explained to an Owner or Referring Veterinarian?

Frame the discussion around the range of possible outcomes instead of a single predicted result. State what the prognostic factor adds to the baseline estimate, and be explicit that the factor modifies risk but does not determine the individual outcome. Use absolute terms where possible, such as the proportion of animals with a given factor that experience the outcome, instead of relative risk alone. Acknowledge the limitations of the evidence, including small sample sizes and inconsistent findings across studies. Offer a monitoring plan that addresses the most likely complications, and document the discussion in the medical record. This approach supports informed decision-making without overstating the certainty of the prognosis.

When Is It Appropriate to Use a Prognostic Factor in Clinical Decisions?

Use a prognostic factor clinically only when it has been validated in a population similar to the patient and when the result would change management. Validation requires confirmation in an independent cohort, also a significant p-value in the derivation study. Consider whether the factor adds predictive value beyond readily available variables such as tumor grade, stage, or surgical margins. For example, histologic grade and margin status are established prognostic factors for canine soft tissue sarcomas, and a new marker should demonstrate incremental value over these standard variables. If the factor does not alter the treatment recommendation or the monitoring interval, its clinical utility is limited regardless of statistical significance.

Related Clinical & Scientific Guides

• Conducting Systematic Reviews of Veterinary Diagnostic Test Accuracy
• Bias in Veterinary Research: Types, Sources, and Mitigation
• Cluster Randomized Trials in Veterinary Research: Design and Analysis

References and Further Reading

• Canine mammary tumors as a model to study human breast cancer: most recent findings.. 2011.
• Physiological biomarkers of chronic stress: A systematic review.. 2021.
• Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.. 2006.
• Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs.. 2011.
• Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.. 2006.
• Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.. 2006.
• ARRIVE Guidelines 2.0 for Reporting Animal Research. PLOS Biology, 2020.
• EQUATOR Network Reporting Guidelines. EQUATOR Network.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Cohort Studies in Veterinary Research: Design and Interpretation
• Observational Studies in Veterinary Medicine: Strengths and Weaknesses
• Conducting Pharmacovigilance Studies in Veterinary Medicine
• Designing Dose-Response Studies in Veterinary Pharmacology
• Appraising Diagnostic Accuracy Studies in Veterinary Medicine

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.